Moderna (MRNA) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
- Market cap
- $95.9B
- As of Nov 5, 2026
- P/E
- -30.44x
- Trailing twelve months
- P/B
- 14.19x
- Latest reported equity
- P/S
- 43.05x
- Trailing twelve months
- ROE
- -46.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $95.9B
- As of Nov 5, 2026
- P/E
- -30.44x
- Trailing twelve months
- P/B
- 14.19x
- Latest reported equity
- P/S
- 43.05x
- Trailing twelve months
- ROE
- -46.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-30.44x
Net loss — not comparable
P/B
14.19x
P/S
43.05x
Earnings and dividend metrics▾
Earnings
EPS
-$7.90
Earnings per share
BPS
$16.94
Book value per share
ROE
-46.6%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $7.90 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $16.94 of net assets.
- ROE — shareholder equity shrank by 46.6% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsApr–Jun 2026(FY2026 Q2)
Revenue increased 2.1% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $142M+2.1%
$241M
Apr–Jun '24
$142M
Apr–Jun '25
$145M
Apr–Jun '26
U.S. Eastern date
ⓘ Notes on these figures▾
- Results for Apr–Jun 2026 are from the 10-Q submitted to SEC EDGAR on Jul 31, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 2.1% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- The next earnings report is scheduled for Nov 6, 2026 (U.S. Eastern).
Filed Jul 31, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Hoge StephenPresident · Oct 15, 2026Open-market sale39,145 shares · $8.6MAvg. price $220.721,636,565 shares held after
- Hoge StephenPresident · Oct 15, 2026Option exercise76,452 shares · $933KAvg. price $12.211,675,710 shares held after
- Hoge StephenPresident · Oct 14, 2026Open-market sale39,224 shares · $8.4MAvg. price $213.4778
Show 2 price lots
- 38,774 shares × $213.47$8.3M
- 450 shares × $214.15$96K
- Hoge StephenPresident · Oct 14, 2026Option exercise76,453 shares · $933KAvg. price $12.211,638,482 shares held after
- Mock James MChief Financial Officer · Oct 5, 2026Shares withheld for taxes704 shares · $134KAvg. price $190.0160,125 shares held after
- Mock James MChief Financial Officer · Oct 5, 2026Option exercise1,454 shares60,829 shares held after
- Hoge StephenPresident · Sep 15, 2026Open-market sale40,281 shares · $5.9MAvg. price $146.071,562,029 shares held after
- Hoge StephenPresident · Sep 15, 2026Option exercise76,452 shares · $933KAvg. price $12.211,602,310 shares held after
- Hoge StephenPresident · Sep 14, 2026Open-market sale40,294 shares · $5.8MAvg. price $144.131,525,858 shares held after
- Hoge StephenPresident · Sep 14, 2026Option exercise76,453 shares · $933KAvg. price $12.211,566,152 shares held after
- Mock James MChief Financial Officer · Sep 10, 2026Open-market sale34,836 shares · $4.7MAvg. price $134.49
Show 2 price lots
- 19,836 shares × $134.49$2.7M
- 15,000 shares × $134.49$2.0M
- Mock James MChief Financial Officer · Sep 10, 2026Option exercise19,836 shares · $614KAvg. price $30.9694,211 shares held after
- Mock James MChief Financial Officer · Sep 4, 2026Shares withheld for taxes5,704 shares · $849KAvg. price $148.8774,375 shares held after
- Klinger Shannon ThymeChief Legal Officer · Sep 4, 2026Shares withheld for taxes5,704 shares · $849KAvg. price $148.8781,340 shares held after
- Klinger Shannon ThymeChief Legal Officer · Sep 4, 2026Option exercise11,797 shares87,044 shares held after
- Mock James MChief Financial Officer · Sep 4, 2026Option exercise11,797 shares80,079 shares held after
- Klinger Shannon ThymeChief Legal Officer · Sep 1, 2026Open-market sale3,471 shares · $486KAvg. price $139.9574,129 shares held after
- Hoge StephenPresident · Sep 1, 2026Shares withheld for taxes4,489 shares · $630KAvg. price $140.341,489,699 shares held after
- Mock James MChief Financial Officer · Sep 1, 2026Shares withheld for taxes1,197 shares · $168KAvg. price $140.3468,282 shares held after
- Klinger Shannon ThymeChief Legal Officer · Sep 1, 2026Shares withheld for taxes1,048 shares · $147KAvg. price $140.3475,247 shares held after
- Klinger Shannon ThymeChief Legal Officer · Sep 1, 2026Option exercise5,637 shares
Show 2 price lots
- 3,471 shares × $30.96$107K
- 2,166 sharesValue not reported
- Mock James MChief Financial Officer · Sep 1, 2026Option exercise2,475 shares69,479 shares held after
- Hoge StephenPresident · Sep 1, 2026Option exercise9,283 shares1,494,188 shares held after
- Hoge StephenPresident · Aug 28, 2026Shares withheld for taxes296 shares · $42KAvg. price $142.771,484,905 shares held after
- Mock James MChief Financial Officer · Aug 28, 2026Shares withheld for taxes160 shares · $23KAvg. price $142.7767,004 shares held after
- Klinger Shannon ThymeChief Legal Officer · Aug 28, 2026Shares withheld for taxes160 shares · $23KAvg. price $142.7774,129 shares held after
- Mock James MChief Financial Officer · Aug 28, 2026Option exercise329 shares67,164 shares held after
- Klinger Shannon ThymeChief Legal Officer · Aug 28, 2026Option exercise329 shares74,289 shares held after
- Hoge StephenPresident · Aug 28, 2026Option exercise611 shares1,485,201 shares held after
- Hoge StephenPresident · Aug 27, 2026Shares withheld for taxes695 shares · $104KAvg. price $149.661,484,590 shares held after
- Mock James MChief Financial Officer · Aug 27, 2026Shares withheld for taxes375 shares · $56KAvg. price $149.6666,835 shares held after
- Klinger Shannon ThymeChief Legal Officer · Aug 27, 2026Shares withheld for taxes375 shares · $56KAvg. price $149.6673,960 shares held after
- Hoge StephenPresident · Aug 27, 2026Option exercise1,437 shares1,485,285 shares held after
- Mock James MChief Financial Officer · Aug 27, 2026Option exercise774 shares67,210 shares held after
- Klinger Shannon ThymeChief Legal Officer · Aug 27, 2026Option exercise774 shares74,335 shares held after
- Bancel StephaneChief Executive Officer · Aug 6, 2026Option exercise252,469 shares · $4.8MAvg. price $19.156,440,260 shares held after
- Bancel StephaneChief Executive Officer · Aug 5, 2026Open-market sale187,044 shares · $11.0MAvg. price $58.796,187,791 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KModerna said on February 3, 2026 that the FDA's Center for Biologics Evaluation and Research (CBER) notified the company it will not initiate a review of the biologics license application (BLA) for its investigational influenza vaccine mRNA-1010 and has issued a Refusal-to-File letter.Published Sep 30, 2026 · Filed Feb 11, 2026Read the summary →
- AI summary8-KModerna entered into a Credit and Guaranty Agreement on November 19, 2025 with Ares Capital Corporation as administrative agent and collateral agent, providing a credit facility of $1,500,000,000.Published Oct 12, 2026 · Filed Nov 24, 2025Read the summary →
- AI summary8-KModerna said at its Analyst Day it targets up to 10% revenue growth in 2026 and expects to expand its seasonal vaccine franchise from 3 to up to 6 approved products by 2028.Published Oct 12, 2026 · Filed Nov 20, 2025Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Moderna (MRNA) stock information
NASDAQ
Moderna (MRNA) is listed on NASDAQ. Its market capitalization is about $95.9B. On trailing-twelve-month earnings the P/E ratio is -30.44, and the P/B ratio is 14.19. Return on equity is -46.6%. These figures are computed in-house from official filings and are reference information only.
Moderna — frequently asked questions
- What is the P/E ratio of Moderna (MRNA)?
- On a trailing-twelve-month basis, MRNA trades at a P/E ratio of -30.44. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Moderna?
- MRNA has a market capitalization of about $95.9B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.